Lung cancer (LC) is associated with ageing, with the average age of affected individuals
being approximately 70 years. However, despite a higher incidence and prevalence among …

Octogenarians with EGFR-mutated non-small cell lung cancer treated by tyrosine-kinase
inhibitor: a multicentric real-world study assessing tolerance and efficacy (OCTOMUT study) …

Lung cancer is the leading cause of cancer‐related mortality in both men and women and
approximately 219,440 new cases of nonsmall cell lung cancer (NSCLC) were estimated to …

Patients aged≤ 50 years are rarely diagnosed with nonsmall cell lung cancer. We
conducted a retrospective cohort study to understand the mutation status of EGFR and the …

Introduction Although standard schedule of gefitinib was the administration of 250 mg tablet
every day, many patients need dose reduction because of toxicities. However, the efficacy of …

The aim of the present study was to analyze the impact of metastatic status on the prognosis
of epithelial growth factor receptor (EGFR) mutation‑positive patients with non‑small cell …

Background In advanced non-small cell lung cancer (NSCLC) patients harboring epidermal
growth factor receptor (EGFR) mutations, those with impaired performance status (PS) …

Abstract Background and Objective To evaluate the efficacy and safety of gefitinib, an orally
active epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in elderly …

Background: Discontinuation of gefitinib treatment is often accompanied by a disease flare.
Some studies have demonstrated a benefit of the use of epidermal growth factor receptor …

BACKGROUND This is the first report of long‐term (> 10 years) safety, tolerability, and
survival data on patients with non–small cell lung cancer (NSCLC) who received treatment …